highperformr logo

Aridis Pharmaceuticals's Overview

Total employees22
HeadquartersLos Gatos
Founded1995

Aridis Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The company's pipeline included innovative treatments for diseases such as ventilator-associated pneumonia (VAP) and cystic fibrosis. Aridis utilized its proprietary MabIgX® technology platform for discovering and developing human mAbs. In late 2023, Aridis Pharmaceuticals filed for Chapter 11 bankruptcy protection and subsequently sold its key assets to various entities in early 2024.

Where is Aridis Pharmaceuticals's Headquarters?

HQ Function

The headquarters served as the central hub for research and development, clinical trial management, and corporate operations before the company's bankruptcy and asset sales.

Notable Features:

The facility likely housed advanced laboratories for antibody discovery, process development, and analytical testing capabilities essential for biopharmaceutical research.

Work Culture:

As a research-focused biopharmaceutical company, the culture was likely science-driven, innovative, and collaborative, with a strong emphasis on addressing unmet medical needs in infectious diseases. Post-bankruptcy, operations at this specific site under Aridis name have ceased or been significantly reduced.

HQ Significance:

Located within the San Francisco Bay Area, a prominent biotech hub, providing access to a skilled talent pool, research institutions, and potential collaborators. This significance has diminished following the company's restructuring.

Values Reflected in HQ: The headquarters likely aimed to reflect values of scientific excellence, innovation in immunotherapy, and a commitment to developing treatments for severe infections.

Location:

Prior to its bankruptcy, Aridis Pharmaceuticals, while headquartered in the US, engaged in activities with global implications, such as planning and conducting clinical trials which often involve international sites and collaborations. Its product candidates were aimed at addressing global health threats. Post-asset sales, its direct global operational presence as Aridis is minimal.

Street Address:

15721 Collection Drive

City:

Los Gatos

State/Province:

CA

Country:

USA

Aridis Pharmaceuticals's Global Presence

Buying Intent Signals for Aridis Pharmaceuticals

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Aridis Pharmaceuticals

As of April 2025, Aridis Pharmaceuticals' leadership includes:

Vu Truong, Ph.D. - Founder, Former Chief Executive Officer
Hasan Jafri, M.D. - Former Chief Business Officer
Michael A. Nazak, CPA - Former Chief Financial Officer
Paul-Andre de Lame, M.D. - Former Chief Medical Officer

Investors of Aridis Pharmaceuticals

Aridis Pharmaceuticals has been backed by several prominent investors over the years, including:

Was publicly traded (NASDAQ: ARDS before delisting)
Serum Institute of India (Acquired key assets including AR-301 and AR-101 in 2024)
Armata Pharmaceuticals (Acquired AR-320 and other assets in 2024)
ADMA Biologics (Acquired AR-105 related assets)

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits4

Following Aridis Pharmaceuticals' Chapter 11 bankruptcy filing in November 2023 and subsequent asset sales in early 2024, significant changes occurred in the executive team, with most, if not all, key executives departing from the original Aridis entity.

Departures

Vu Truong, Ph.D., Vu Truong ceased his role as CEO following the company's bankruptcy filing and subsequent asset sales.
Hasan Jafri, M.D., Hasan Jafri's role as CBO ended in conjunction with the company's bankruptcy and asset divestiture.
Michael A. Nazak, CPA, Michael A. Nazak's tenure as CFO concluded during the company's Chapter 11 process.

Technology (Tech Stack) used by Aridis Pharmaceuticals

Discover the tools Aridis Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Aridis Pharmaceuticals Email Formats and Examples

Prior to its operational wind-down, Aridis Pharmaceuticals likely used standard corporate email formats. The most common formats are variations of first name, last name, and initials.

[first_initial][last]@aridispharma.com (e.g., jdoe@aridispharma.com) or [first].[last]@aridispharma.com

Format

vtruong@aridispharma.com

Example

20%

Success rate

News and media

Armata Pharmaceuticals Press ReleaseApril 1, 2024

Aridis Pharmaceuticals news title: Armata Pharmaceuticals Acquires Pseudomonas aeruginosa Monoclonal Antibody Candidate from Aridis Pharmaceuticals

Armata Pharmaceuticals announced it has acquired from Aridis Pharmaceuticals its Pseudomonas aeruginosa monoclonal antibody (mAb) candidate, AR-320 (now AP-PA03), along with an exclusive license to a portfolio of other anitbody candidates....more

PR Newswire / Aridis PharmaceuticalsFebruary 12, 2024

Aridis Pharmaceuticals news title: Aridis Pharmaceuticals Announces Closing of Asset Sale to Serum Institute of India for AR-301 and AR-101

Aridis Pharmaceuticals, Inc. announced the closing of the sale of its AR-301 (tosatoxumab) and AR-101 (panobacumab) assets to the Serum Institute of India Private Limited (SIIPL)....more

GlobeNewswire / Aridis PharmaceuticalsNovember 15, 2023

Aridis Pharmaceuticals news title: Aridis Pharmaceuticals Voluntarily Files for Relief Under Chapter 11 of the Bankruptcy Code to Facilitate Sale Process

Aridis Pharmaceuticals, Inc. announced that it and its wholly-owned subsidiary, Aridis Pharmaceuticals (Europe) Limited, have voluntarily filed for relief under Chapter 11 of the Bankruptcy Code in the District of Delaware. The Company intends to use the proceedings to facilitate a sale of its assets....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Aridis Pharmaceuticals, are just a search away.